Zachary F. Zimmerman, M.D., Ph.D.
Senior Vice President, Clinical Development
Zachary F. Zimmerman, M.D., Ph.D., senior vice president, clinical development at BlossomHill Therapeutics, is a hematologist and medical oncologist with broad experience in the clinical development of cutting-edge therapies for both solid tumors and hematologic malignancies. Prior to joining BlossomHill Therapeutics, Dr. Zimmerman was vice president of clinical development at NiKang Therapeutics, where he was responsible for leading clinical development activities for multiple oncology programs across several solid tumor indications. Previously, Dr. Zimmerman worked at Turning Point Therapeutics, where he led the clinical development of small-molecule inhibitors for oncogene-driven solid tumors. Prior to Turning Point, he held roles at Amgen in both medical affairs and global clinical development, where his work on the development of the bispecific T-cell engager blinatumomab ultimately led to multiple approvals in pediatric and adult acute lymphoblastic leukemia indications in the U.S., EU and Japan.
Dr. Zimmerman received a doctorate in immunology and a Doctor of Medicine from the University of Miami Miller School of Medicine. He completed residency training in internal medicine at the University of Washington and fellowship training in hematology and medical oncology at the University of Washington/ Fred Hutchinson Cancer Research Center in Seattle.